Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,972 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group. See WA, et al. Among authors: carroll k. J Urol. 2002 Aug;168(2):429-35. J Urol. 2002. PMID: 12131282 Clinical Trial.
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Iversen P, et al. Among authors: carroll k. Urology. 2004 May;63(5):928-33. doi: 10.1016/j.urology.2004.02.011. Urology. 2004. PMID: 15134983 Clinical Trial.
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Iversen P, et al. Among authors: carroll k. J Urol. 2004 Nov;172(5 Pt 1):1871-6. doi: 10.1097/01.ju.0000139719.99825.54. J Urol. 2004. PMID: 15540741 Clinical Trial.
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GR. Iversen P, et al. Among authors: carroll k. Urology. 1998 Mar;51(3):389-96. doi: 10.1016/s0090-4295(98)00004-1. Urology. 1998. PMID: 9510340 Clinical Trial.
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG). Iversen P, et al. Among authors: carroll k. Eur Urol. 2002 Sep;42(3):204-11. doi: 10.1016/s0302-2838(02)00311-1. Eur Urol. 2002. PMID: 12234503 Clinical Trial.
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Wirth MP, et al. Among authors: carroll k. J Urol. 2004 Nov;172(5 Pt 1):1865-70. doi: 10.1097/01.ju.0000140159.94703.80. J Urol. 2004. PMID: 15540740 Clinical Trial.
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K. Tyrrell CJ, et al. Among authors: carroll k. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):476-83. doi: 10.1016/j.ijrobp.2004.03.022. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380582 Clinical Trial.
1,972 results